Lantern Pharma (NASDAQ:LTRN) Trading Down 0.6% – What’s Next?

Posted by Geri Gentry on Sep 16th, 2026

Lantern Pharma Inc. (NASDAQ:LTRN – Get Free Report)’s stock price was down 0.6% on Tuesday . The stock traded as low as $1.67 and last traded at $1.70. 128,115 shares changed hands during mid-day trading, a decline of 13% from the average daily volume of 147,335 shares. The stock had previously closed at $1.71.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Weiss Ratings raised shares of Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. Wall Street Zen downgraded shares of Lantern Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Lantern Pharma presently has an average rating of “Sell”.

Check Out Our Latest Research Report on Lantern Pharma

Lantern Pharma Stock Performance

The firm has a market capitalization of $21.73 million, a P/E ratio of -1.05 and a beta of 2.30. The firm has a 50-day moving average of $2.51 and a 200-day moving average of $2.73.

Lantern Pharma (NASDAQ:LTRN – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.19).

Hedge Funds Weigh In On Lantern Pharma

A number of hedge funds have recently bought and sold shares of LTRN. Susquehanna International Group LLP bought a new position in Lantern Pharma during the 2nd quarter valued at about $59,000. Bank of New York Mellon Corp bought a new stake in shares of Lantern Pharma in the second quarter worth approximately $89,000. BlackRock Inc. purchased a new position in shares of Lantern Pharma during the second quarter valued at approximately $93,000. Renaissance Technologies LLC raised its holdings in shares of Lantern Pharma by 5.1% during the first quarter. Renaissance Technologies LLC now owns 116,000 shares of the company’s stock valued at $159,000 after purchasing an additional 5,600 shares during the last quarter. Finally, Empery Asset Management LP bought a new position in Lantern Pharma during the second quarter valued at approximately $3,513,930. Hedge funds and other institutional investors own 28.62% of the company’s stock.

Lantern Pharma Company Profile

(Get Free Report)

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.